Patent 11946085 was granted and assigned to Amgen on April, 2024 by the United States Patent and Trademark Office.
The present invention relates to methods of upregulating the high mannose glycoform content of a recombinant protein during a mammalian cell culture by manipulating the mannose to total hexose ratio in the cell culture media formulation.